Atopic dermatitis burden scale for adults: Development and validation of a new assessment tool

Acta Dermato-Venereologica

Volumn 95, Issue 6, 2015, Pages 700-705

  Taïeb, Alain ^a   Boralevi, Franck ^a   Seneschal, Julien ^a   Merhand, Stephanie ^b   Georgescu, Victor ^c   Taïeb, Charles ^d   Ezzedine, Khaled ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b French Association of Eczema   (France)

^c Medical Department   (France)

^d Centre d'Immunologie Pierre Fabre   (France)

Author keywords

Adult; Atopic dermatitis; Individual burden; Questionnaire; Validation

Indexed keywords

ADULT; ARTICLE; ATOPIC DERMATITIS BURDEN SCALE FOR ADULT; CONCURRENT VALIDITY; DERMATOLOGY LIFE QUALITY INDEX; DISCRIMINANT VALIDITY; FEMALE; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; PSYCHOMETRY; SHORT FORM 12; SKIN DISEASE ASSESSMENT; TEST RETEST RELIABILITY; VALIDATION STUDY; AGED; ATOPIC DERMATITIS; COST OF ILLNESS; MIDDLE AGED; PATHOLOGY; PSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; COST OF ILLNESS; DERMATITIS, ATOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOMETRICS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES;

EID: 84932103938     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1945     Document Type: Article

References (39)

1. Bieber T. Atopic dermatitis. N Engl J Med 2008; 358: 1483-1494.
2. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: Section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 2014; 70: 338-351.
3. Ellis CN, Mancini AJ, Paller AS, Simpson EL, Eichenfield LF. Understanding and managing atopic dermatitis in adult patients. Semin Cutan Med Surg 2012; 31 (3 Suppl): S18-S22.
4. Margolis JS, Abuabara K, Bilker W, Hoffstad O, Margolis DJ. Persistence of mild to moderate atopic dermatitis. JAMA Dermatol 2014; 150: 593-600.
5. de Monchy JG, Demoly P, Akdis CA, Cardona V, Papadopoulos NG, Schmid-Grendelmeier P, et al. Allergology in Europe, the blue print. Allergy 2013; 68: 1211-1218.
6. Darsow U, Wollenberg A, Simon D, Taïeb A, Werfel T, Oranje A, et al. Difficult to control atopic dermatitis. World Allergy Organ J 2013; 6: 6.
7. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012; 26: 1045-1060.
8. Schäkel K, Döbel T, Bosselmann I. Future treatment options for atopic dermatitis - Small molecules and beyond. J Dermatol Sci 2014; 73: 91-100.
9. Silverberg JI. Atopic dermatitis: an evidence-based treatment update. Am J Clin Dermatol 2014; 15: 149-164.
10. Boguniewicz M, Leung DY. The ABC's of managing patients with severe atopic dermatitis. J Allergy Clin Immunol 2013; 132: 511-512.e5.
11. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderateto- severe atopic dermatitis: a systematic review. J Allergy Clin Immunol 2014; 133: 429-438.
12. Simon D, Bieber T. Systemic therapy for atopic dermatitis. Allergy 2014; 69: 46-55.
13. Kemp AS. Atopic eczema: its social and financial costs. J Paediatr Child Health 1999; 35: 229-231.
14. Wittkowski A, Richards HL, Griffiths CE, Main CJ. The impact of psychological and clinical factors on quality of life in individuals with atopic dermatitis. J Psychosom Res 2004; 57: 195-200.
15. Sánchez-Pérez J, Daudén-Tello E, Mora AM, Lara Surinyac N. Impact of atopic dermatitis on health-related quality of life in Spanish children and adults: the PSEDA study. Actas Dermosifiliogr 2013; 104: 44-52.
16. Barbeau M, Lalonde H. Burden of atopic dermatitis in Canada. Int J Dermatol 2006; 45: 31-36.
17. Suh DC, Sung J, Gause D, Raut M, Huang J, Choi IS. Economic burden of atopic manifestations in patients with atopic dermatitis - analysis of administrative claims. J Manag Care Pharm 2007; 13: 778-789.
18. Guex JJ, Rahhali N, Taieb C. The patient's burden of chronic venous disorders: construction of a questionnaire. Phlebology 2010; 25: 280-285.
19. Sibaud V, Dalenc F, Chevreau C, Roché H, Delord JP, Mourey L, et al. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 2011; 16: 1469-1478.
20. Boccara O, Méni C, Léauté-Labreze C, Hadj-Rabia S, Bodemer C, Voisard JJ, et al. Haemangioma family burden: creation of a specific questionnaire. Acta Derm Venereol 2015; 95: 78-82.
21. Dufresne H, Hadj-Rabia S, Méni C, Sibaud V, Bodemer C, Taïeb C. Family burden in inherited ichthyosis: creation of a specific questionnaire. Orphanet J Rare Dis 2013; 8: 28.
22. Rannou F, Bertin P, Grange L, Branchoux S, Dachicourt JN, Taieb C. The burden of osteoarthritis: development and validation of a new assessment tool (BONe'S). Curr Med Res Opin 2014; 30: 741-751.
23. Méni C, Bodemer C, Toulon A, Merhand S, Perez-Cullell N, Branchoux S, et al. Atopic dermatitis burden scale: creation of a specific burden questionnaire for families. J Eur Acad Dermatol Venereol 2013; 27: 1426-1432.
24. Seidenberg M, Haltiner A, Taylor MA, Hermann BB, Wyler A. Development and validation of a multiple ability self-report questionnaire. J Clin Exp Neuropsychol 1994; 16: 93-104.
25. Leidy NK, Revicki DA, Genesté B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999; 2: 113-127.
26. Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol 1994; 131: 406-416.
27. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrica 1951; 16: 297-334.
28. Nunally J. Psychometric Theory. New York, McGraw-Hill, 1978.
29. Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, et al. Principles of good practice for the translation and cultural adaptation process for patientreported outcomes (PRO) measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 2005; 8: 94-104.
30. Lapidus CS, Kerr PE. Social impact of atopic dermatitis. Med Health R I 2001; 84: 294-295.
31. Su VY, Chen TJ, Yeh CM, Chou KT, Hung MH, Chu SY, et al. Atopic dermatitis and risk of ischemic stroke: A nationwide population-based study. Ann Med 2014; 46: 84-89.
32. Betlloch I, Izu R, Lleonart M, Ferrer M, Ferrando J; Investigadores del estudio ACTIDA. Attitude of the adult patient with atopic dermatitis to the disease and its treatment: the ACTIDA Study. Actas Dermosifiliogr 2010; 101: 143-150.
33. Fivenson D, Arnold RJ, Kaniecki DJ, Cohen JL, Frech F, Finlay AY. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Manag Care Pharm 2002; 8: 333-342.
34. Lapidus CS. Role of social factors in atopic dermatitis: the US perspective. J Am Acad Dermatol 2001; 45(1 Suppl): S41-S43.
35. Kiebert G, Sorensen SV, Revicki D, Fagan SC, Doyle JJ, Cohen J, et al. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol 2002; 41: 151-158.
36. Rehal B, Armstrong AW. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010. PLoS One 2011; 6: e17520.
37. Stalder JF, Barbarot S, Wollenberg A, Holm EA, De Raeve L, Seidenari S, et al. Patient-Oriented SCORAD (POSCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy 2011; 66: 1114-1121.
38. European Medicines Agency. Committee for Medicinal Products for Human Use (2005). Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. Available from: http://www.emea.europa.eu/docs/ en_GB/document_library/Scientific_guideline/2009/09/ WC500003637.pdf. Accessed Feb 24, 2014.
39. US Department of Health and Human Services Food and Drug Administration (2009). Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM193282.pdf. Accessed Feb 24, 2014.